

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1 (original) A method of treating cancer in a patient comprising administering to the patient an amount of oxaliplatin in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have a synergistic anticancer effect.
- 2 (original) A method according to claim 1 wherein in addition to oxaliplatin other chemotherapeutic agents are also delivered to the patient with the oxaliplatin.
- 3 (original) A method according to claim 2 wherein an effective anticancer amount of 5-FU and or LV are administered with oxaliplatin or a oxaliplatin based therapy'
- 4 (original) A method according to claim 2 wherein other chemotherapeutic agents that may be employed in the method include systemic chemotherapy drugs such as irinotecan or capecitabine.
- 5 (currently amended) A method according to ~~anyone of the preceding claims~~ claim 1 wherein the patient is also treated with an anti-angiogenesis factor.

- 6 (currently amended) A method according to ~~anyone of the preceding~~
~~claims~~ claim 1 wherein the patient is also treated with other anticancer agents
including antibodies targeted against a cancer cells or the blood vessels
supplying the cancer cells or antibodies targeting EGF and VEGF.
- 7 (currently amended) A therapeutic combination of anticancer agents
comprising an effectively therapeutic amount of oxaliplatin and an amount of
radionuclide-doped agent suitable for SIRT to effectively treat a cancer,
~~characterised in that~~ wherein ~~the combination when administered to a patient~~
~~leads~~ two therapies when administered to a patient lead to a synergistic
anticancer effect that is therapeutically more efficacious than either treatment
when administered alone.
- 8 (original) A therapeutic composition according to 7 wherein oxaliplatin is
combined with 5-fluorouracil and leucovorin.
- 9 (original) A therapeutic composition according to 8 wherein oxaliplatin is
combined with other systemic chemotherapy drugs such as irinotecan or
capecitabine.
- 10 (original) A therapeutic composition according to 8 wherein oxaliplatin is
combined with an anti-angiogenesis factor.
- 11 (original) A therapeutic composition according to 8 wherein oxaliplatin is
combined with an anticancer agent including antibodies targeted against a

cancer cells or the blood vessels supplying the cancer cells or antibodies targeting EGF and VEGF.

12 (canceled)

13 (New) The method according to claim 1 wherein the cancer is a primary or secondary cancer.